RSK1 is an exploitable dependency in myeloid malignancies [RNA-seq]

RSK1 is an exploitable dependency in myeloid malignancies HEL cells were treated in duplicate with DMSO control or 10 µM PMD-026 for 24 hours. MV4-11 cells were treated in duplicate with DMSO control, 500 nM PMD-026, or 50 nM quizartinib for 24 hours. Three unique primary patient CD14+ monocytes were treated with DMSO control or 5 µM PMD-026 for 6 hours.